Skip to main content

Carl J Pepine, MD

Cardiologist (Heart Specialist)

Photo of Carl J Pepine

Research at a glance

Top areas of exploration

  • Coronary Disease , 197 publications
  • Myocardial Ischemia , 186 publications
  • Coronary Artery Disease , 153 publications
  • Hypertension , 143 publications

Research activity

1,077 publications

53,715 citations

Why is this important?

Focus

My career has focused on improving our understanding of mechanisms underlying ischemic heart disease (IHD) and related adverse outcomes. I have conducted extensive investigations in coronary artery disease (CAD), hypertension, treatment resistant hypertension, vascular biology, and therapeutic applications related to vascular dysfunction. My work has centered on how IHD becomes manifest with and without large coronary artery obstructive disease (CAD). Much of this work is concentrated in women with known or suspect IHD. A major goal of clinical research is development of actionable information of sufficient power to alter medical care and improve patient health by information obtained through performance of clinical trials. To this end, I conceived and led the first randomized controlled international mega-trial of blood pressure control for patients with CAD (INVEST). My experience also includes being a principal investigator (PI) in multiple NHLBI-funded projects [Women’s Ischemia Syndrome Evaluation (WISE), WISE-CVD, WISE HFpEF, MayWEST, Asymptomatic Cardiac Ischemia Pilot (ACIP), Psychophysiologic Interventions of Myocardial Ischemia (PIMI), Bypass Angioplasty Revascularization Investigation 2-Diabetes Trial (BARI2D), etc.] and many other industry-sponsored studies. More recently I have been working in cardiovascular recovery and regeneration with cell based therapies as a PI in the NHLBI Cardiovascular Cell Therapy Network (CCTRN)- 1 and 2, as well as studies funded by the the cell and gene biomedical industry.

Active clinical trials

EVOLVE

The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic…

Investigators
Michael R Massoomi, Carl J Pepine
Status
Accepting Candidates
Ages
18 Years - 99 Years
Sexes
All
Gut Organoid Study

The study compared basic properties of gut epithelia of hypertensive and normotensive reference subjects. The study determined if there are fundamental differences in the gut epithelium in hypertension compared to normotension. Specifically, this…

Investigator
Carl J Pepine
Status
Accepting Candidates
Ages
18 Years - 80 Years
Sexes
All

My publications

1077 publications

2025

High‐Throughput Screening for Prescribing Cascades Among Real‐World Angiotensin‐ II Receptor Blockers ( ARBs ) Initiators

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

Publisher's site

2025

Hypertension and the Gut Microbiome: A Science Advisory From the American Heart Association.

Hypertension (Dallas, Tex. : 1979)

PubMed Publisher's site

2025

Blood Pressure Lowering and Risk of Cancer: Individual Participant-Level Data Meta-Analysis and Mendelian Randomization Studies.

JACC. CardioOncology

PubMed Publisher's site

2025

Exclusive lactation is associated with improved lipid profile postpartum.

American heart journal plus : cardiology research and practice

PubMed Publisher's site

2025

A lightweight graph neural network to predict long-term mortality in coronary artery disease patients: an interpretable causality-aware approach.

Journal of biomedical informatics

PubMed Publisher's site